Branisteanu Daciana Elena, Munteanu Alice Elena, Dolofan Bogdan Mihai, Popescu Elena Gabriela, Vittos Oana
Faculty of Medicine, General, Dermatology Discipline, University of Medicine and Pharmacy "Gr. T. Popa", 700115 Iasi, Romania.
Central Military Emergency University Hospital "Dr. Carol Davila", 010825 Bucharest, Romania.
Life (Basel). 2025 Feb 27;15(3):377. doi: 10.3390/life15030377.
Chronic venous disease (CVeD) affects millions of patients globally, being a multifactorial progressive condition that significantly impacts the quality of life of individuals. Micronized Purified Flavonoid Fraction (MPFF) is the most utilized and studied venoactive drug because of its safety and effectiveness. This study is a real-world, prospective, observational, multicenter cohort study including patients diagnosed with CVeD who were receiving one tablet of MPFF 1000 mg/day for at least one month and who visited medical facilities in Romania in June-July 2022. We aimed to assess their adherence to pharmacological treatment. The intensity of CVeD symptoms was assessed with the Visual Analog Scale (VAS), while adherence to conservative treatment was evaluated using the Morisky Medication Adherence Scale (MMAS-8) at study inclusion (Visit 1 (V1)) and 8 weeks later, at the study's end (Visit 3 (V3)). This study recruited 1267 patients diagnosed with CVeD, and the statistical analysis set included 1200 patients, the majority of whom were female (71.5%), ≥51 years old (81.8%), and overweight (41.2%) or obese (33.8%), with a mean Body Mass Index (BMI) value (±SD) of 28.9 ± 5.1 kg/m, classified using the Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) clinical categories as CEAP C3 (38.7%) and C2 (22.6%) at baseline. Mean MMAS-8 scores increased from 6.2 ± 1.9 (V1) to 6.7 ± 1.7 (V3) ( < 0.001). Despite improvement in treatment adherence throughout this study, novel strategies are needed to improve medication adherence and overall health outcomes in CVeD.
慢性静脉疾病（CVeD）在全球影响着数百万患者，是一种多因素的渐进性疾病，严重影响个人生活质量。微粉化纯化黄酮类化合物（MPFF）因其安全性和有效性，是使用最广泛且研究最多的静脉活性药物。本研究是一项真实世界、前瞻性、观察性、多中心队列研究，纳入了被诊断为CVeD且每天服用一片1000毫克MPFF至少一个月，并于2022年6月至7月在罗马尼亚医疗机构就诊的患者。我们旨在评估他们对药物治疗的依从性。使用视觉模拟量表（VAS）评估CVeD症状的严重程度，同时在研究纳入时（第1次就诊（V1））和8周后、研究结束时（第3次就诊（V3）），使用Morisky药物依从性量表（MMAS - 8）评估对保守治疗的依从性。本研究招募了1267名被诊断为CVeD的患者，统计分析样本包括1200名患者，其中大多数为女性（71.5%），年龄≥51岁（81.8%），超重（41.2%）或肥胖（33.8%），平均体重指数（BMI）值（±标准差）为28.9±5.1kg/m²，根据临床、病因、解剖和病理生理（CEAP）临床分类，基线时CEAP C3为38.7%，C2为22.6%。MMAS - 8平均得分从6.2±1.9（V1）提高到6.7±1.7（V3）（P<0.001）。尽管在本研究中治疗依从性有所改善，但仍需要新的策略来提高CVeD患者的药物依从性和整体健康结局。
